| Old Articles: <Older 18371-18380 Newer> |
|---|
 |
The Motley Fool
November 13, 2006
Tom Taulli |
MSC.Software's Best Friend MSC wants to turn its operations around. And that means teaming up with IBM. Investors, take note.   |
The Motley Fool
November 13, 2006
Tim Hanson |
The Dangers of Shady Deals If you're investing in China and India, you should know this: Of the businesses in the world's 30 leading exporting countries, those in China and India are the most like to pay bribes. |
The Motley Fool
November 13, 2006 |
Urban Outfitters' Messy Margins: Fool by Numbers The clothing retailer released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 13, 2006
Rick Aristotle Munarriz |
4 Stocks That Took a Hike Companies with growing yields can make you rich in more ways than the obvious. SYSCO... Perrigo... Bandag... Laidlaw... |
The Motley Fool
November 13, 2006
Ryan Fuhrmann |
Landry's Reworks Its Menu Landry's continues its transition to a casino operator and high-end restaurateur. Investors, take note. |
The Motley Fool
November 13, 2006
Tom Taulli |
Moto Goes Mobile -- Corporate Mobile Over the next few years, Motorola should certainly be well-positioned in the corporate mobile market -- which appears to be a strong growth segment. Investors, take note. |
The Motley Fool
November 13, 2006
Rick Aristotle Munarriz |
The Knot's It Today's beating of the market may seem tame by more recent standards -- and this quarter may prove challenging, as fully diluted shares will increase now that the secondary and acquisition shares will no longer be weighted -- but The Knot is clearly doing things right. |
The Motley Fool
November 13, 2006 |
Lee's Breaking News: Fool by Numbers The publisher released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
The Motley Fool
November 13, 2006
Rich Smith |
Ceradyne, Sera Fine So far this year, Ceradyne has now notched a 90% year-over-year improvement in sales. Earnings are up 195%, and earnings per share a less impressive but still impressive 169% (thanks to 10% stock dilution). |
| <Older 18371-18380 Newer> Return to current articles. |
